Outlook Therapeutics Inc. Shares Close the Week 23.1% Higher - Weekly Wrap

The company saw its shares close the week 23.1% higher than last week, with trading volume lower than its 30 day average.

Mar 12, 2021 by Kwhen Finance Editors

Outlook Therapeutics Inc. Shares Close the Week 23.1% Higher - Weekly Wrap
Outlook Therapeutics Inc. shares closed this week 23.1% higher than it did at the end of last week. The stock is currently up 72.3% year-to-date, up 245.1% over the past 12 months, and down 47.5% over the past five years. This week, the Dow Jones Industrial Average rose 4.1%, and the S&P 500 rose 2.7%.

Trading Activity

  • Shares traded as high as $2.37 and as low as $1.77 this week.
  • Trading volume this week was 78.1% higher than the 10-day average and 7.9% higher than the 30-day average.
  • Beta, a measure of the stock’s volatility relative to the overall market stands at 0.9.

Technical Indicators

  • The Relative Strength Index (RSI) on the stock was between 30 and 70.
  • MACD, a trend-following momentum indicator, indicates a downward trend.
  • The stock closed below its Bollinger band, indicating it may be oversold.

Fundamentals & Catalysts

  • Over the past 12 months the company generated $-26,406,745 in earnings before interest and taxes from $5 million in revenue. It currently holds $23 million in cash and $18 million in debt.
  • Its forward price-to-earnings (P/E) ratio of -6.382352874043904 is higher than its current P/E ratio of -7.89, implying that analysts are expecting a decrease in earnings.
  • The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -0.12. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
  • The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 2.76 which means it currently has $2.76 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
  • The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 34.32. This means that the stock is trading at a premium of 34 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
  • The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 64.29.
  • The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 61.00.

P/E

-7.89

EBITDA

$-26,406,745

P/Book

34.32

Mkt Cap

$388M

P/Sales

64.29

Revenue

$5M

EPS (TTM)

-1.00

PEG Ratio

-0.12

EV/Revenue

61.00

Total Cash

$23M

Debt/Equity

2.76

Forward P/E

-6.38

Current Debt

$18M

Gross Profit

$5M

Dividend Date

-

Earnings Date

2021-02-16

Profit Margin

-8.41

Revenue/Share

0.03

Total Revenue

$5M

Enterprise Val

$357M

Put/Call Ratio

0.00

Revenue/Employee

0.00

Market Comparative Performance

  • The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis
  • The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis
  • The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis
NameDoD %ΔYTD %Δ1 Yr %52-Week H %52-Week L %
Outlook Therapeutics Inc.0.672.3245.1
Dow Jones Industrial Average0.97.644.4-0.882.1
S&P 500 Index0.15.449.0-0.981.9
Health Care0.21.231.3-4.660.1

Peer Group Comparative Performance

  • The company's stock price performance year-to-date beats the peer average by 326.9%
  • The company's stock price performance over the past 12 months lags the peer average by -80.3%
NameMKT CAP (USD)P/EYTD %Δ1 Yr %Δ52-Week H %52-Week L %
Outlook Therapeutics Inc.OTLK-7.972.3245.1
Peer AvgN/A-2.016.91246.1
Outlook Therapeutics Inc.OTLK-7.972.3245.1
Organovo Holdings Inc.ONVO0-4.64739.2

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?

Tags: